

ZIMBABWE Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Zimbabwe					
2. Grant number: 1820-ZWE-09a-X					
3. Date of Decision Letter: 13 December 2017					
4. Date of the Partnership Framework Agreement: 17 May 2013					
5. Programme title: New vaccine support (NVS), Measles-Rubella Second Dose Routine					
6. Vaccine type: Measles-Rubella					
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED					
8. Programme duration¹: 2015 -2020					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2015-2017	2018	2019	2020	Total ²
Programme Budget (US\$)	US\$441,500 ³	US\$62,500	US\$188,500	US\$197,500	US\$890,000
10. Vaccine introduction grant (in US\$): Not applicable					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴					
Type of supplies to be purchased with Gavi funds in each year	2015-2017	2018			
Number of Measles vaccines doses		222,200			
Annual Amounts (US\$)	US\$441,500 ⁵	US\$62,500			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
13. Self-procurement: Not applicable					
14. Co-financing obligations: Not applicable					
15. Operational support for campaigns: Not applicable					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

16. Additional reporting requirements: Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable	
18. Other conditions:	
Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine second dose, with country funding the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.	
	2018
Number of doses of vaccines for Measles Second Dose approved by Gavi.	222,200
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	59,994
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	97,078
Number of doses of Measles-Rubella vaccine to be funded by country.	125,122
Amount for Measles-Rubella vaccines to be funded by country in US\$ (excluding freight and insurance).	77,326
In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.	
In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017